NO135801B - - Google Patents
Download PDFInfo
- Publication number
- NO135801B NO135801B NO2721/72A NO272172A NO135801B NO 135801 B NO135801 B NO 135801B NO 2721/72 A NO2721/72 A NO 2721/72A NO 272172 A NO272172 A NO 272172A NO 135801 B NO135801 B NO 135801B
- Authority
- NO
- Norway
- Prior art keywords
- antigen
- antibody
- serum
- australia
- suspension
- Prior art date
Links
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 33
- 239000000427 antigen Substances 0.000 claims description 71
- 102000036639 antigens Human genes 0.000 claims description 71
- 108091007433 antigens Proteins 0.000 claims description 71
- 210000002966 serum Anatomy 0.000 claims description 38
- 239000002245 particle Substances 0.000 claims description 37
- 239000000725 suspension Substances 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 108010071390 Serum Albumin Proteins 0.000 claims description 4
- 102000007562 Serum Albumin Human genes 0.000 claims description 4
- 239000007900 aqueous suspension Substances 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 229920003002 synthetic resin Polymers 0.000 claims description 3
- 239000000057 synthetic resin Substances 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- 239000011347 resin Substances 0.000 description 18
- 229920005989 resin Polymers 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 230000004520 agglutination Effects 0.000 description 12
- 238000010790 dilution Methods 0.000 description 12
- 239000012895 dilution Substances 0.000 description 12
- 239000004793 Polystyrene Substances 0.000 description 9
- 229920002223 polystyrene Polymers 0.000 description 9
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 241000700199 Cavia porcellus Species 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 241000700198 Cavia Species 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 239000007975 buffered saline Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 230000028654 Type IV pili-dependent aggregation Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000012817 gel-diffusion technique Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB3609771A GB1390617A (en) | 1971-07-31 | 1971-07-31 | Diagnostic reagents test method and pack |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO135801B true NO135801B (da) | 1977-02-21 |
| NO135801C NO135801C (da) | 1977-06-08 |
Family
ID=10384922
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO2721/72A NO135801C (da) | 1971-07-31 | 1972-07-28 | |
| NO3782/72A NO138394C (no) | 1971-07-31 | 1972-10-20 | Fremgangsmaate for aa fastslaa naervaer av australia-antigen i en blodproeve |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO3782/72A NO138394C (no) | 1971-07-31 | 1972-10-20 | Fremgangsmaate for aa fastslaa naervaer av australia-antigen i en blodproeve |
Country Status (19)
| Country | Link |
|---|---|
| JP (1) | JPS4829487A (da) |
| AR (1) | AR192962A1 (da) |
| AT (1) | AT316752B (da) |
| AU (1) | AU472607B2 (da) |
| BE (1) | BE787014A (da) |
| BR (1) | BR7205058D0 (da) |
| CH (1) | CH572621A5 (da) |
| DK (1) | DK144988C (da) |
| ES (2) | ES405387A1 (da) |
| FI (1) | FI55408C (da) |
| FR (1) | FR2148081B1 (da) |
| GB (1) | GB1390617A (da) |
| IE (1) | IE36589B1 (da) |
| IL (1) | IL39991A0 (da) |
| IT (1) | IT963332B (da) |
| NL (1) | NL163877C (da) |
| NO (2) | NO135801C (da) |
| SE (1) | SE410768B (da) |
| ZA (1) | ZA725257B (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3992517A (en) * | 1975-02-19 | 1976-11-16 | Pfizer Inc. | Detection of hepatitis B surface antigen by latex agglutination |
| US4642285A (en) * | 1975-09-29 | 1987-02-10 | Diamedix Corporation | Sandwich EIA for antigen |
| US4474878A (en) * | 1975-09-29 | 1984-10-02 | Cordis Laboratories, Inc. | Sandwich EIA for antigen associated with hepatitis |
| CA1100037A (en) * | 1977-03-11 | 1981-04-28 | Chung-Mei Ling | Hb.sub.c ag coated on solid phase |
| JP2572035B2 (ja) * | 1986-02-12 | 1997-01-16 | ユニチカ株式会社 | マルチフイラメント糸 |
-
0
- BE BE787014D patent/BE787014A/xx not_active IP Right Cessation
-
1971
- 1971-07-31 GB GB3609771A patent/GB1390617A/en not_active Expired
-
1972
- 1972-07-24 IE IE1035/72A patent/IE36589B1/xx unknown
- 1972-07-25 SE SE7209728A patent/SE410768B/xx unknown
- 1972-07-25 IL IL39991A patent/IL39991A0/xx unknown
- 1972-07-25 IT IT27383/72A patent/IT963332B/it active
- 1972-07-26 AU AU45020/72A patent/AU472607B2/en not_active Expired
- 1972-07-27 FI FI2104/72A patent/FI55408C/fi active
- 1972-07-27 DK DK373072A patent/DK144988C/da active
- 1972-07-27 AT AT648072A patent/AT316752B/de not_active IP Right Cessation
- 1972-07-28 BR BR5058/72A patent/BR7205058D0/pt unknown
- 1972-07-28 NO NO2721/72A patent/NO135801C/no unknown
- 1972-07-28 FR FR7227335A patent/FR2148081B1/fr not_active Expired
- 1972-07-31 ES ES405387A patent/ES405387A1/es not_active Expired
- 1972-07-31 CH CH1134472A patent/CH572621A5/xx not_active IP Right Cessation
- 1972-07-31 ZA ZA725257A patent/ZA725257B/xx unknown
- 1972-07-31 ES ES405388A patent/ES405388A1/es not_active Expired
- 1972-07-31 AR AR243342A patent/AR192962A1/es active
- 1972-07-31 JP JP47076027A patent/JPS4829487A/ja active Pending
- 1972-07-31 NL NL7210503.A patent/NL163877C/xx not_active IP Right Cessation
- 1972-10-20 NO NO3782/72A patent/NO138394C/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO135801C (da) | 1977-06-08 |
| DK144988B (da) | 1982-07-19 |
| FR2148081A1 (da) | 1973-03-11 |
| DE2237204A1 (de) | 1973-02-08 |
| GB1390617A (en) | 1975-04-16 |
| CH572621A5 (da) | 1976-02-13 |
| FR2148081B1 (da) | 1977-08-26 |
| SE410768B (sv) | 1979-10-29 |
| NL163877B (nl) | 1980-05-16 |
| DE2237204B2 (de) | 1977-04-07 |
| NO138394B (no) | 1978-05-16 |
| AU4502072A (en) | 1974-02-07 |
| BE787014A (fr) | 1973-01-31 |
| AU472607B2 (en) | 1976-05-27 |
| IE36589B1 (en) | 1976-12-08 |
| ES405388A1 (es) | 1975-07-01 |
| FI55408B (fi) | 1979-03-30 |
| FI55408C (fi) | 1979-07-10 |
| NO138394C (no) | 1978-08-23 |
| BR7205058D0 (pt) | 1973-11-01 |
| AT316752B (de) | 1974-07-25 |
| IL39991A0 (en) | 1972-09-28 |
| ZA725257B (en) | 1973-04-25 |
| DK144988C (da) | 1982-12-06 |
| AR192962A1 (es) | 1973-03-21 |
| JPS4829487A (da) | 1973-04-19 |
| NL163877C (nl) | 1980-10-15 |
| IT963332B (it) | 1974-01-10 |
| IE36589L (en) | 1973-01-31 |
| ES405387A1 (es) | 1975-07-01 |
| NL7210503A (da) | 1973-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3088875A (en) | Immunological diagnostics utilizing polystyrene latex particles of 0.15 to 0.25 micron | |
| JP3551678B2 (ja) | ヘモグロビンＡ１ｃの測定法及びキット | |
| JPS6243138B2 (da) | ||
| US4711841A (en) | Method for determining one or more antigens in a sample | |
| US4588681A (en) | Process for producing adult T cell leukemia associated antigen | |
| DK144395B (da) | Fremgangsmaade og proevningssaet til proevning for tilstedevaerelsen af hepatitis b overfladeantigen i menneskeblod | |
| US4313927A (en) | Immunoassay method for detecting viral antibodies in whole blood samples | |
| US5043289A (en) | Method and device for assaying immunologically reactive substances of clinical interest | |
| US3562384A (en) | Immunological indicator and test system | |
| NO135801B (da) | ||
| JPH05310849A (ja) | 多官能性親水性球状微粒子、その製造方法及びその使用方法 | |
| KR100896396B1 (ko) | 점착성 미세소포의 제거 방법 | |
| McArthur et al. | A rapid micro-method for screening eel sera for antibodies against the digenean Telogaster opisthorchis Macfarlane, 1945. | |
| US4090846A (en) | Indirect latex test for determination of fibrinogen degradation products | |
| NO875198L (no) | Fastfase - analysemetode. | |
| Walls et al. | Evaluation of a hemagglutination test for amebiasis, using a commercial antigen | |
| JP3328053B2 (ja) | 免疫凝集反応による抗体又は抗原の濃度定量法 | |
| US3497319A (en) | Diagnostic reagent | |
| JP3048306B2 (ja) | フィブリン分解産物及び／又はフィブリノーゲン分解産物測定試薬及びその定量方法 | |
| US4617260A (en) | RIA assay for HBcAg | |
| JPH0954091A (ja) | 抗赤血球抗体の測定法 | |
| JPH09502263A (ja) | ヒドラジン誘導体化細胞 | |
| O'neill et al. | Evaluation of a modified FTA-ABS test multispot FTA-ABS. | |
| NO173297B (no) | Fremgangsmaate for detektering eller bestemmelse av en analytt | |
| WO1995002186A1 (en) | New diagnostic assay for detection of syphilis |